ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.36) by 2.21 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the same period last year.